New cocktail aims to knock out leukemia for good
NCT ID NCT01496976
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tested a combination of three drugs—ofatumumab, high-dose methylprednisolone, and lenalidomide—in 45 people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal was to see if this approach could make all signs of cancer disappear and keep it away for a long time. Participants first received ofatumumab and steroids, then a consolidative phase with ofatumumab and lenalidomide.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ofatumumab, high-dose methylprednisolone, and lenalidomide
What this could lead to
If successful, this combination could offer a long-lasting treatment option for people with untreated CLL/SLL, potentially keeping the cancer in remission for years.
What could go wrong
This is a small, early-phase trial (45 participants) with no control group, so results may not apply to everyone. The drugs can cause serious side effects like infections, blood clots, and nerve damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States